VU 0364770 is primarily used in research settings as a potent and selective positive allosteric modulator (PAM) of the metabotropic glutamate receptor subtype 4 (mGluR4). Its application is significant in neuroscience studies, particularly in investigating the role of mGluR4 in the central nervous system. Researchers utilize this compound to explore potential therapeutic strategies for neurological disorders such as Parkinson's disease, anxiety, and epilepsy. By enhancing mGluR4 activity, VU 0364770 helps in understanding the modulation of glutamate signaling, which is crucial for synaptic plasticity and neuronal communication. This makes it a valuable tool in preclinical studies aimed at developing novel treatments for brain-related conditions.